IFF (IFF) Q3 2026 earnings review
IFF raises its full-year floor, but fourth-quarter profit will dip
IFF's flavor and fragrance divisions carried the quarter while its health unit stalled and portfolio sales triggered heavy write-downs. Underlying sales grew 5% in constant currencies, beating the low-single-digit second-half pace the prior plan pointed to. Chief executive Erik Fyrwald lifted the bottom of the full-year outlook, but warned that fourth-quarter profit will soften on higher costs in Health & Biosciences.
| Sales from businesses owned a year ago (constant currency) | +5% 0–4% implied H2 pace |
|---|---|
| Profit per share, excluding one-offs and amortization | $0.83 +9% from a year ago |
| Net debt to credit-adjusted EBITDA | 2.75x 2.5x in Q2 (target 2.0–2.5x) |
| Full-year EBITDA outlook, excluding one-offs | Low end +$20M middle of the range: $1.575B |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because strong volume in Scent and Taste offset a setback in Health & Biosciences and a jump in debt leverage. Beating the implied third-quarter pace allowed IFF to raise the bottom of its annual ranges, yet keeping the top end flat leaves fourth-quarter underlying sales growth slowing to about 2% by our math. One caution: finishing the $500 million buyback ahead of the Food Ingredients sale pushed net debt to 2.75 times EBITDA, and legal charges for fragrance probes reached $115 million this year.
The question now is whether third-quarter volume strength marks durable market share gains or just customer restocking before a fourth-quarter drop. Either the company set its fourth-quarter outlook cautiously, or higher costs and weak health demand will pull profit margins down to 19%. Fourth-quarter underlying sales and Health & Biosciences margins will settle it.
🐂 Bull Case
Volume Growth in Scent and Taste Lifted the Outlook
IFF makes flavors, fragrances, and biological ingredients for food and consumer goods. After growth reached 6% in the second quarter, the full-year outlook pointed to a low-single-digit pace in the second half. Instead, third-quarter sales from businesses owned a year ago rose 5% in constant currencies, and reported sales grew 4% to $1.94 billion.
- Taste underlying sales: up 6%, led by double-digit growth in Greater Asia
- Scent underlying sales: up 6%, with consumer fragrances up high-single digits
- Fine fragrance underlying sales: up mid-single digits on top of a 20% jump a year ago
Higher volumes drove both divisions, so the beat proved that customer demand held up through the summer. Because the first nine months ran ahead of plan, chief executive Erik Fyrwald raised the bottom of the full-year sales outlook by $100 million.
What to watch: fourth-quarter underlying sales growth, where the full-year outlook implies about 2% by our math. Beating that figure would show that IFF set its fourth-quarter plan with the same caution it used in the third.
Scent Margin Expanded Despite Input Cost Pressure
Going into the second half, Scent carried the heaviest exposure to higher energy and logistics costs because customer price surcharges take four to six quarters to catch up. Even so, the fragrance division grew operating EBITDA, excluding one-offs, by 10% in constant currencies to $139 million.
Scent's operating EBITDA margin rose 0.7 percentage points from a year ago to 20.2%, or 0.8 percentage points on a comparable currency-neutral basis. Volume growth in consumer and fine fragrances absorbed the factory and freight inflation before the 2027 pricing catch-up even arrived.
What to watch: Scent's fourth-quarter operating EBITDA margin. Holding above last year's 15.7% fourth-quarter level would confirm that factory volumes can cover energy costs on their own.
Nine-Month Cash Flow Nearly Tripled From Last Year
IFF tied employee bonuses to cash generation this year after free cash flow — operating cash flow minus capital spending — fell short of its original target in 2025. For the first nine months of 2026, operating cash flow across continuing and discontinued businesses rose by $288 million to $820 million, and free cash flow rose by $245 million to $371 million.
Smaller inventory builds and $204 million of cash retained through accounts payable drove the nine-month improvement. However, by our math, third-quarter free cash flow was negative $7 million against $378 million in the first half, as receivables absorbed $291 million year to date.
What to watch: fourth-quarter free cash flow against the separation working-capital outflows. Staying positive in the fourth quarter would keep full-year cash generation well ahead of last year's $256 million.
🐻 Bear Case
Health & Biosciences Stalled and Will Drag Down Q4
"IFF delivered a solid third quarter, with improved sales and profitability across all divisions," Fyrwald said. That framing glosses over a sharp slowdown in Health & Biosciences, which makes enzymes and probiotics: its underlying sales growth dropped to 1% from 5% in both the first and second quarters.
The company had previously aimed for its North America Health business to return to growth in the second half. Instead, the release noted that "Mid-single digit growth in Food Biosciences and Grain Processing more than offset a decline in Health." Worse, Fyrwald warned that "we expect fourth-quarter profitability to be softer, particularly in Health & Biosciences, reflecting higher costs as well as reinvestments to strengthen the business."
By our math, the full-year outlook leaves $306 million to $356 million of adjusted operating EBITDA for the fourth quarter. At the middle of the range, that means an 18.9% margin, down from 20.8% this quarter.
What to watch: Health & Biosciences fourth-quarter underlying sales and EBITDA margin. A second quarter of 1% growth alongside a margin drop below 24% would show the reinvestments are not yet fixing the health unit.
Portfolio Sales Triggered Write-Downs and Higher Legal Bills
IFF is selling lower-margin units to focus on core flavors, scents, and biosciences. Fyrwald said "The separation of Food Ingredients is progressing well, and we are on track with our timeline to close" by the end of the second quarter of 2027, and the CitraSource sale closed on July 1.
- Loss on assets held for sale: $236 million, for Botanicals & Food Enhancements and CitraSource
- Goodwill write-down: $23 million, for Botanicals & Food Enhancements
- Regulatory costs: $34 million in the quarter and $115 million year to date
Those divestiture write-downs pushed the company to a $134 million pre-tax loss from continuing operations. Meanwhile, selling and administrative expenses rose 1.3 percentage points of sales to 19.9% because of legal fees and provisions "for the ongoing investigations of the fragrance businesses and legal fees incurred."
What to watch: cash payments for legal settlements and the closing of the Botanicals & Food Enhancements sale in the fourth quarter. New provisions would eat into the cash proceeds from the smaller portfolio sales.
Early Buyback Pushed Debt Leverage Above Target
In August, the board authorized a $2.5 billion share buyback program, starting with a $500 million accelerated repurchase planned for the second half of 2026. IFF finished the entire $500 million program in the third quarter, spending $513 million on treasury stock by our math and trimming its diluted share count for adjusted profit from 257 million to 254 million.
Because the $3.8 billion Food Ingredients sale does not close until mid-2027, the company funded the buyback while drawing a $1.0 billion term loan and raising short-term debt. Net debt rose by $622 million in the quarter to $5.79 billion, pushing net debt to credit-adjusted EBITDA up to 2.75 times, above the 2.0 to 2.5 times target.
What to watch: net debt to credit-adjusted EBITDA at year-end. Any delay in regulatory approvals for the Food Ingredients sale would leave leverage above 2.5 times into 2027.
Risks This Quarter Didn't Answer
Four standing concerns from earlier quarters received no new data in the third-quarter earnings release.
- Stranded overhead costs: no update on removing the roughly $100 million of corporate expenses left behind by the Food Ingredients unit; the call and 2027 plan will test the timeline.
- Weight-loss drugs and processed food: no commentary in the release on how GLP-1 adoption affects Taste volumes; conference call remarks will show management's current view.
- Commodity fragrance competition: Fragrance Ingredients grew mid-single digits, but the release gave no detail on price pressure from Indian and Chinese rivals.
- Tax accounting controls: after two prior revisions to tax lines, the upcoming quarterly Form 10-Q filing will show whether any new control issues arose.
👓 Other Themes
Currency Tailwinds Hold Steady as Macro Conditions Shift
Fyrwald noted that IFF is operating "Amid changing macroeconomic conditions" while keeping its currency assumptions unchanged for the full year. Foreign exchange added 1 percentage point to reported sales growth in the third quarter, and the company still expects currency translation to lift full-year sales growth by about 1% and adjusted operating EBITDA growth by about 2%.
💲 Other KPIs
Profit per share excluding one-offs and acquisition amortization rose 9.2% from $0.76 a year ago, faster than the 6.5% rise in the second quarter. On a reported basis, IFF posted a loss of $0.50 per share because of the $236 million held-for-sale write-down and $34 million in legal provisions.
Spending on property, plant and equipment rose 10.6% from $406 million in the first nine months of 2025. The ingredient maker spent $148 million in the third quarter alone by our math, bringing nine-month capital spending to 7.7% of continuing sales as it invests in factory capacity.
Spending on product development rose 4.9% from $162 million a year ago and matched the $170 million spent in the second quarter. At 8.8% of sales, research spending held steady as a share of revenue while supporting new flavor and fragrance wins.
🔮 Guidance
Raised. The company lifted the bottom of its full-year sales range by $100 million, putting the middle of the range at $7.55 billion. By our math, that leaves $1.75 billion for the fourth quarter, a 2.5% drop from last year's $1.79 billion as recent business sales come out of the numbers.
Raised. Management lifted the floor by 1 percentage point after underlying sales grew 4% in the first nine months. By our math, the 3.5% middle of the range leaves about 2% underlying growth for the fourth quarter, down from 5% in the third quarter.
Raised. The flavor and fragrance group lifted the low end by $20 million, moving the middle of the range to $1.575 billion. By our math, that leaves $331 million for the fourth quarter, up 1.8% from $325 million a year ago, with the margin dropping to 18.9% on higher Health & Biosciences costs.
Raised. IFF raised the bottom of the range by 1 percentage point after delivering 7% growth through the first nine months. By our math, the 6.5% middle of the range implies about 4.7% growth in the fourth quarter, slowing from 6% this quarter.
❓ Key Questions
When will the North America Health business stop shrinking?
Management previously targeted a second-half return to growth for North America Health, but the unit declined again in the third quarter and needs extra investment in the fourth.
What is Driving the Fourth-Quarter Cost Increase in Health & Biosciences?
Fyrwald warned that fourth-quarter profit will soften on higher costs and reinvestments in Health & Biosciences, which implies the company's EBITDA margin falls nearly 2 percentage points from the third quarter.
How Much Legal Liability Remains in the Fragrance Investigations?
IFF booked another $34 million for fragrance investigations this quarter, bringing the nine-month total to $115 million, without stating when European and UK regulators will finish their probes.
What is the Quarterly Plan to Cut the $100M Stranded Costs?
With the Food Ingredients sale set to close by mid-2027, investors still lack a segment breakdown and quarterly removal schedule for the $100 million of shared corporate overhead.